Osteonecrosis of the Jaw and Atypical Femoral Fractures

Elizabeth Shane, Sundeep Khosla, David Burr

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Bisphosphonates reduce the risk of spine and nonspine fractures, including hip fractures. However, they are associated with osteonecrosis of the jaw (ONJ) and atypical femoral fractures. The incidence of ONJ is highest in patients with malignancy receiving high doses of intravenous bisphosphonates and denosumab, and is considerably lower in patients receiving lower doses of bisphosphonates for osteoporosis and Paget disease, with estimates ranging from 1 in 10,000 to 1 in 250,000. Major risk factors for ONJ are antiresorptive drug potency, longer duration of use, periodontal disease, dental extractions, or trauma. The pathogenesis is likely related to suppression of bone remodeling, common to both bisphosphonates and denosumab, and infection and inflammation. Atypical subtrochanteric and femoral shaft fractures are associated with long-term bisphosphonate, and more recently with denosumab use, but also occur in patients who have never been exposed to these drugs. Although the estimated relative risks of atypical femoral fractures range from xx to xx in patients on bisphosphonates, their absolute risk is low, ranging from 3.2 to 50 cases per 100,000 person-years. Given the very low incidence of ONJ and atypical femur fractures in patients treated with bisphosphonates for osteoporosis versus the marked reduction in fracture risk associated with these drugs, the risk to benefit ratio for the use of bisphosphonates and denosumab clearly favors treating patients with a prior fragility fracture, a spine or femur neck T-score below -2.5, or at high risk of fractures.

Original languageEnglish (US)
Title of host publicationOsteoporosis: Fourth Edition
PublisherElsevier Inc.
Pages1873-1908
Number of pages36
ISBN (Print)9780124158535
DOIs
StatePublished - Jun 2013

Fingerprint

Femoral Fractures
Osteonecrosis
Diphosphonates
Jaw
Osteoporosis
Spine
Bone Density Conservation Agents
Tooth Extraction
Fracture Fixation
Bone Remodeling
Femur Neck
Incidence
Hip Fractures
Periodontal Diseases
Pharmaceutical Preparations
Femur
Inflammation
Denosumab
Wounds and Injuries
Infection

Keywords

  • Atypical femoral fractures (AFFs)
  • Femoral shaft fractures
  • Osteonecrosis of the jaw (ONJ)

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Shane, E., Khosla, S., & Burr, D. (2013). Osteonecrosis of the Jaw and Atypical Femoral Fractures. In Osteoporosis: Fourth Edition (pp. 1873-1908). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-415853-5.00081-9

Osteonecrosis of the Jaw and Atypical Femoral Fractures. / Shane, Elizabeth; Khosla, Sundeep; Burr, David.

Osteoporosis: Fourth Edition. Elsevier Inc., 2013. p. 1873-1908.

Research output: Chapter in Book/Report/Conference proceedingChapter

Shane, E, Khosla, S & Burr, D 2013, Osteonecrosis of the Jaw and Atypical Femoral Fractures. in Osteoporosis: Fourth Edition. Elsevier Inc., pp. 1873-1908. https://doi.org/10.1016/B978-0-12-415853-5.00081-9
Shane E, Khosla S, Burr D. Osteonecrosis of the Jaw and Atypical Femoral Fractures. In Osteoporosis: Fourth Edition. Elsevier Inc. 2013. p. 1873-1908 https://doi.org/10.1016/B978-0-12-415853-5.00081-9
Shane, Elizabeth ; Khosla, Sundeep ; Burr, David. / Osteonecrosis of the Jaw and Atypical Femoral Fractures. Osteoporosis: Fourth Edition. Elsevier Inc., 2013. pp. 1873-1908
@inbook{f283691fcb364a4292c7f927b1d69800,
title = "Osteonecrosis of the Jaw and Atypical Femoral Fractures",
abstract = "Bisphosphonates reduce the risk of spine and nonspine fractures, including hip fractures. However, they are associated with osteonecrosis of the jaw (ONJ) and atypical femoral fractures. The incidence of ONJ is highest in patients with malignancy receiving high doses of intravenous bisphosphonates and denosumab, and is considerably lower in patients receiving lower doses of bisphosphonates for osteoporosis and Paget disease, with estimates ranging from 1 in 10,000 to 1 in 250,000. Major risk factors for ONJ are antiresorptive drug potency, longer duration of use, periodontal disease, dental extractions, or trauma. The pathogenesis is likely related to suppression of bone remodeling, common to both bisphosphonates and denosumab, and infection and inflammation. Atypical subtrochanteric and femoral shaft fractures are associated with long-term bisphosphonate, and more recently with denosumab use, but also occur in patients who have never been exposed to these drugs. Although the estimated relative risks of atypical femoral fractures range from xx to xx in patients on bisphosphonates, their absolute risk is low, ranging from 3.2 to 50 cases per 100,000 person-years. Given the very low incidence of ONJ and atypical femur fractures in patients treated with bisphosphonates for osteoporosis versus the marked reduction in fracture risk associated with these drugs, the risk to benefit ratio for the use of bisphosphonates and denosumab clearly favors treating patients with a prior fragility fracture, a spine or femur neck T-score below -2.5, or at high risk of fractures.",
keywords = "Atypical femoral fractures (AFFs), Femoral shaft fractures, Osteonecrosis of the jaw (ONJ)",
author = "Elizabeth Shane and Sundeep Khosla and David Burr",
year = "2013",
month = "6",
doi = "10.1016/B978-0-12-415853-5.00081-9",
language = "English (US)",
isbn = "9780124158535",
pages = "1873--1908",
booktitle = "Osteoporosis: Fourth Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Osteonecrosis of the Jaw and Atypical Femoral Fractures

AU - Shane, Elizabeth

AU - Khosla, Sundeep

AU - Burr, David

PY - 2013/6

Y1 - 2013/6

N2 - Bisphosphonates reduce the risk of spine and nonspine fractures, including hip fractures. However, they are associated with osteonecrosis of the jaw (ONJ) and atypical femoral fractures. The incidence of ONJ is highest in patients with malignancy receiving high doses of intravenous bisphosphonates and denosumab, and is considerably lower in patients receiving lower doses of bisphosphonates for osteoporosis and Paget disease, with estimates ranging from 1 in 10,000 to 1 in 250,000. Major risk factors for ONJ are antiresorptive drug potency, longer duration of use, periodontal disease, dental extractions, or trauma. The pathogenesis is likely related to suppression of bone remodeling, common to both bisphosphonates and denosumab, and infection and inflammation. Atypical subtrochanteric and femoral shaft fractures are associated with long-term bisphosphonate, and more recently with denosumab use, but also occur in patients who have never been exposed to these drugs. Although the estimated relative risks of atypical femoral fractures range from xx to xx in patients on bisphosphonates, their absolute risk is low, ranging from 3.2 to 50 cases per 100,000 person-years. Given the very low incidence of ONJ and atypical femur fractures in patients treated with bisphosphonates for osteoporosis versus the marked reduction in fracture risk associated with these drugs, the risk to benefit ratio for the use of bisphosphonates and denosumab clearly favors treating patients with a prior fragility fracture, a spine or femur neck T-score below -2.5, or at high risk of fractures.

AB - Bisphosphonates reduce the risk of spine and nonspine fractures, including hip fractures. However, they are associated with osteonecrosis of the jaw (ONJ) and atypical femoral fractures. The incidence of ONJ is highest in patients with malignancy receiving high doses of intravenous bisphosphonates and denosumab, and is considerably lower in patients receiving lower doses of bisphosphonates for osteoporosis and Paget disease, with estimates ranging from 1 in 10,000 to 1 in 250,000. Major risk factors for ONJ are antiresorptive drug potency, longer duration of use, periodontal disease, dental extractions, or trauma. The pathogenesis is likely related to suppression of bone remodeling, common to both bisphosphonates and denosumab, and infection and inflammation. Atypical subtrochanteric and femoral shaft fractures are associated with long-term bisphosphonate, and more recently with denosumab use, but also occur in patients who have never been exposed to these drugs. Although the estimated relative risks of atypical femoral fractures range from xx to xx in patients on bisphosphonates, their absolute risk is low, ranging from 3.2 to 50 cases per 100,000 person-years. Given the very low incidence of ONJ and atypical femur fractures in patients treated with bisphosphonates for osteoporosis versus the marked reduction in fracture risk associated with these drugs, the risk to benefit ratio for the use of bisphosphonates and denosumab clearly favors treating patients with a prior fragility fracture, a spine or femur neck T-score below -2.5, or at high risk of fractures.

KW - Atypical femoral fractures (AFFs)

KW - Femoral shaft fractures

KW - Osteonecrosis of the jaw (ONJ)

UR - http://www.scopus.com/inward/record.url?scp=84903064618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903064618&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-415853-5.00081-9

DO - 10.1016/B978-0-12-415853-5.00081-9

M3 - Chapter

AN - SCOPUS:84903064618

SN - 9780124158535

SP - 1873

EP - 1908

BT - Osteoporosis: Fourth Edition

PB - Elsevier Inc.

ER -